Product image of Juneflecad (Flecainide Acetate) supplied by GNH India

Juneflecad

Active Ingredient:
Flecainide Acetate
Origin:
EU

Juneflecad (Flecainide Acetate)

Flecainide acetate, the active ingredient in Juneflecad, is a Class Ic antiarrhythmic presented as an oral tablet for systemic use. It is employed to manage ventricular arrhythmias and atrial fibrillation in adult patients where rhythm control is required. It is indicated for patients with documented supraventricular or ventricular tachyarrhythmias when other therapies are unsuitable.

GNH India supplies Juneflecad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU pharmacopeial standards and is distributed under a valid marketing authorization.

Manufacturer / TM Owner

Laboratorios Liconsa, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Juneflecad (flecainide acetate) is used to treat cardiac rhythm disorders by targeting abnormal electrical conduction.

  • Ventricular arrhythmias: restores normal rhythm and reduces episodes of ventricular tachycardia.
  • Atrial fibrillation: helps maintain sinus rhythm in patients with paroxysmal or persistent AF.
  • Supraventricular tachyarrhythmias: suppresses rapid atrial rates when other agents are unsuitable.

How It Works

  • Flecainide acetate blocks the fast inward sodium channels (Na⁺) in cardiac myocytes, slowing phase 0 depolarization. This reduces conduction velocity across atrial and ventricular tissue, prolongs the refractory period, and stabilises abnormal automaticity, thereby preventing the propagation of premature impulses that cause arrhythmias.

Side Effects

Adverse reactions may occur with flecainide therapy and should be monitored.

Common Side Effects

  • Dizziness: transient light‑headedness, especially after dose initiation.
  • Visual disturbances: blurred vision or photopsia.
  • Nausea: mild gastrointestinal upset.
  • Fatigue: reduced energy levels.

Serious or Rare Side Effects

  • Proarrhythmia: new or worsening arrhythmias, including ventricular tachycardia.
  • Heart block: atrioventricular conduction delay or complete block.
  • Severe hypotension: marked drop in blood pressure.
  • Pulmonary edema: fluid accumulation in lungs, particularly in patients with pre‑existing heart failure.

Precautions & Warnings

Before prescribing Juneflecad, clinicians should consider several safety measures.

  • ECG monitoring: perform baseline and periodic ECGs to detect conduction changes.
  • Structural heart disease: avoid in patients with prior myocardial infarction or significant cardiomyopathy.
  • Renal/hepatic impairment: adjust dosing and monitor plasma levels in moderate to severe dysfunction.
  • Concomitant drugs: review other agents that affect cardiac conduction or CYP2D6 metabolism.
  • Specialist supervision: use under the guidance of a cardiologist experienced in antiarrhythmic therapy.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Flecainide may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., quinidine, propafenone): can markedly increase flecainide plasma concentrations.
  • Other sodium‑channel blockers (e.g., lidocaine, procainamide): additive risk of conduction slowing and proarrhythmia.
  • Beta‑blockers combined with high‑dose flecainide: may cause excessive bradycardia.

Moderate Interactions (Monitor Closely)

  • Digoxin: monitor serum levels as flecainide can enhance its effects.
  • Diuretics: watch for electrolyte disturbances that may predispose to arrhythmias.
  • ACE inhibitors or ARBs: observe blood pressure changes when combined with flecainide‑induced hypotension.

Frequently Asked Questions

Juneflecad contains flecainide acetate and is prescribed for the management of ventricular arrhythmias and atrial fibrillation. It may also be used in selected cases of supraventricular tachyarrhythmias when other rhythm‑control agents are not appropriate.

Flecainide acetate blocks fast inward sodium channels in cardiac muscle cells, slowing the rapid upstroke of the action potential. This reduces conduction velocity and prolongs the refractory period, helping to prevent the spread of abnormal electrical impulses that cause arrhythmias.

The dosage of Juneflecad is individualized by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should determine the appropriate dose.

Safety data for flecainide acetate in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the Juneflecad product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Juneflecad (flecainide) is a Class Ic agent, distinguished by potent sodium‑channel blockade and rapid onset of action. Compared with Class III agents such as amiodarone, flecainide has a shorter half‑life and fewer thyroid or pulmonary side effects, but it requires careful use in patients without structural heart disease due to a higher proarrhythmic risk.

Juneflecad should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain product stability.

Juneflecad is taken orally, usually as a tablet swallowed whole with a glass of water. The exact timing (e.g., with or without food) is determined by the prescribing physician based on the individual treatment plan.

The most serious risks include proarrhythmia (new or worsening arrhythmias), atrioventricular heart block, severe hypotension, and, rarely, pulmonary edema. Patients should be monitored closely, especially during therapy initiation and dose adjustments.

Juneflecad is contraindicated in patients with a history of myocardial infarction, significant structural heart disease, severe left ventricular dysfunction, or known hypersensitivity to flecainide. It should also be avoided in individuals taking other strong sodium‑channel blockers without specialist supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Flecainide Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT